Skip To Content
J. Bradley  White

J. Bradley White

Partner, Intellectual Property

Chair: Intellectual Property


Contact Information

bwhite@osler.com

tel: 613.787.1101

Office

Ottawa

Areas of Expertise
Bar Admission

Ontario, 1998

Education
  • University of Windsor, LL.B.
  • University of Waterloo, M.Sc.
  • University of Western Ontario, B.Sc.
Language(s)
English

Brad is a partner and Chair of the National Intellectual Property Department. Brad practises intellectual property law with an emphasis on complex patent litigation and patent prosecution. He provides a number of clients with strategic advice on the enforcement of their patent rights, including the coordination and management of litigation strategies throughout multiple jurisdictions.  Brad has appeared as lead counsel before the Federal Court of Appeal, Federal Court and the Ontario Superior Court.  He is also a registered Patent Agent, and specializes in Canadian and foreign patent and industrial design prosecution, strategic reviews of IP portfolios, patentability, patent infringement and validity opinions, and advising on world-wide patent portfolio management and enforcement. Brad is also registered to practise before the United States Patent and Trademark Office and currently serves on the Patent Legislation and Industrial Design Committees for the Intellectual Property Institute of Canada. He is also a former associate editor of the Canadian Patent Reporter.

  • Managing IP 2015: IP Star, Patent (Canada)
  • Managing IP 2015: IP Star, Patent licensing (Canada)
  • Managing IP 2015: IP Star, Patent litigation (Canada)
  • Managing IP 2015: IP Star, Patent opinion (Canada)
  • Managing IP 2015: IP Star, Patent strategy and counselling (Canada)
  • Benchmark Litigation Canada 2015: Intellectual Property
  • Chambers Global: The World’s Leading Business Lawyers 2015: recognized both for Intellectual Property Litigation and Intellectual Property
  • The Best Lawyers in Canada 2015: Intellectual Property Law (recognized for Patent and Litigation)
  • Recognized as one of the World’s Leading Patent Practitioners by Intellectual Asset Management  Patent 1000 2012-2015
  • The Canadian Legal Lexpert Directory 2015: Intellectual Property; Intellectual Property Litigation
  • Managing IP 2014: IP Star – Canada
  • Expert Guides: Patent Practicioners, 2013
  • Intellectual Asset Magazine (IAM) 250 Worlds Leading Patent Litigators 2011: ranked as one of the world’s leading patent litigators
  • International Asset Magazine (IAM) Life Science 250 2010: ranked as one of the world’s leading life sciences litigators
  • Lexpert 2009 Guide to the Leading US/Canada Cross-Border Litigation Lawyers: ranked as a Canadian Litigation lawyer to watch

  • Royal Ottawa Golf Club, Past Board Member (3 years service)

  • Intellectual Property Institute of Canada
  • American Intellectual Property Law Association
  • International Association for the Protection of Intellectual Property (AIPPI)
  • Canadian Bar Association

Mylan Pharmaceuticals ULC :  Lead outside counsel to Mylan Pharmaceuticals ULC in patent and other matters. Successfully represented Mylan Pharmaceuticals ULC in an application commenced by Takeda Pharmaceuticals in Federal Court of Canada (T-1161-13) under the Patented Medicines (Notice of Compliance) Regulations in respect of the drug pantoprazole magnesium (TECTA®).   2015 FC 751

Presently representing or successfully settled numerous complex pharmaceutical and general litigation matters including:

  • Novartis Pharmaceuticals v Mylan Pharmaceuticals ULC et al. T-365-14
  • Janssen Inc. v Mylan Pharmaceuticals ULC et al. T-1577-14
  • Amgen Canada Inc. v Mylan Pharmaceuticals ULC et al. T-2056-14
  • AstraZeneca Canada Inc. et al. v Mylan Pharmaceuticals ULC et al. T-336-15
  • Sanofi-Aventis v Mylan Pharmaceuticals ULC T-1441-12
  • Takeda Pharmaceuticals et al v Mylan Pharmaceuticals ULC T-1451-11
  • AstraZeneca et al v Mylan Pharmaceuticals ULC et al. 2011 FC 312, 2012 FCA 109
  • Pfizer Canada Inc et al v Mylan Pharmaceuticals ULC et al.2011 FC 547; 2012 FCA 103
  • Lundbeck Canada Inc. v Mylan Pharmaceuticals ULC et al. (2009) 73 C.P.R. (4th) 69 (F.C.T.D.); (2010) 88 C.P.R. (4th) 325 (F.C.A.), SCC 34068
  • Nycomed v. Genpharm ULC et al. 2008 FC 330, (2008), 64 C.P.R. (4th) 388 (F.C.T.D.)
  • Janssen-Ortho Inc. and Daiichi Pharmaceutical Co, Ltd.  v. Novopharm Ltd. et al. 2006 FC 1333, (2006) 57 C.P.R. (4th) 6 and 58 (F.C.T.D.)
  • Abbott Laboratories v. ratiopharm inc. et al. (2005), 45 C.P.R. (4th) 468 (F.C.T.D.)
  • Abbott Laboratories v. ratiopharm inc. et al. (2005), 42 C.P.R. (4th) 20 and 121 (F.C.T.D.)
  • Janssen-Ortho Inc. v. Novopharm Ltd. et al. (2005), 39 C.P.R. (4th) 197 (F.C.A.)
  • Janssen-Ortho Inc. v. Novopharm Ltd. et al. (2004), 35 C.P.R.(4th) 353 (F.C.T.D.), appeal dismissed (2005), 40 C.P.R. (4th) 1 (F.C.A.)
  • Abbott Laboratories v. ratiopharm inc. et al. (2004), 31 C.P.R. (4th) 321 (F.C.A.)

Samsung Bioepis:  Representing Samsung Bioepis in first case brought under the Patented Medicines (Notice of Compliance) Regulations in relation to blockbuster biopharmaceutical ENBREL® (etanercept).

  • Amgen Canada Inc. and Immunex Corporation v. Samsung Bioepis Co., Ltd. and The Minister of Health T-1283-15

Standard Innovation Corporation: In the role of world-wide coordinating litigation and IP counsel acted or acting for Standard Innovation Corporation, including in the following cases:

  • Appeal from the US International Trade Commission, Investigation No. 337-TA-823, United States Court of Appeals for the Federal Circuit, No. 2013-1582, Lelo Inc. & Leloi AB v. International Trade Commission and Standard Innovation (US) Corp. & Standard Innovation Corporation
  • District Court Action before the United States District Court of Northern California  5:13-cv-01393-PSG: Lelo Inc v  Standard Innovation  US Corp  and  Standard  Innovation Corporation
  • Two Inter Partes Review Re: Standard Innovation Corporation (Petitioner) v. Lelo Inc. [Patent Owner; Cases IPR2014-00148 and IPR2014-00907, Re: United States Patent No. 7,749,178 (“the ‘178 Patent”)].
  • Ex Parte reexamination of the United States Patent No. 7,931,605 (“the ‘605 Patent”)
  • Lead Canadian IP  counsel to Standard Innovation Corporation including in T-925-12: Standard Innovation Corporation  v. LELOI AB et Lelo Inc., 1531011 Ontario Inc., Cana International Distributing Inc., Landco Import International Inc. and TBMBM Inc.

Scientific Publications

  • J.B.White, M.Dulick and P.F. Bernath, The High Resolution Infrared Emission Spectra of InH and InD, J. Mol. Spec., 169, 410-420 (1995).
  • T. Karkanis, Z. Morbi, J.B. White, M. Dulick and P.F. Bernath, The High Resolution Infrared Emission Spectrum of InF, Canadian J. Phys., 72, 1213-1217 (1994).
  • R. LeBlanc, J.B. White and P,F. Bernath, Improved Rotational Constants far HCI and HF, J, Mol, Spec., 164, 574 (1994).
  • J.B. White, M,Dulick and P.F. Bernath, The High Resolution Infrared Emission Spectra of AIH and AID J. Chem. Phys., 99, 8371 (Dec. 1993).
  • J.Campbell, M.Dulick, D.Klapstein, J.B. White and P.F.Bernath, The High Resolution Infrared Emission Spectra of GaH and GaD, J Chem. Phys., 99, 8379 (Dec. 1993).

Other Publications

  • The Uncertain Future of Predicted Utility, Managing IP Magazine (IP Focus 2014 Canada), September 2014
  • Key issues for senior life sciences executives, IP in the Life Sciences Industries 2014 (This article first appeared in Intellectual Asset Management issue 66, published by The IP Media Group. To view the report in full, go to www.iam-magazine.com)